Literature DB >> 19867284

MECHANISM OF THE REACTION BETWEEN BILE SALTS AND BLOOD SERUM AND THE EFFECT OF CONJUGATION IN THE FORMATION OF BILE SALTS.

A W Sellards1.   

Abstract

THESE EXPERIMENTS SUGGEST THE FOLLOWING CONCLUSIONS CONCERNING HEMOLYTIC ACTION: 1. It is probably the proteid part of the serum which inhibits the bile salts. 2. The cholalic acid group is the active part of the bile salt molecule. 3. The protection afforded by bile salts against serum is of especial interest from the following considerations: (a) The protective action is a property apparently peculiar to proteids obtained from blood serum. It is not given satisfactorily by egg albumen. (b) The conjugation of cholalic acid with glycocoll in the formation of the bile salts is of some advantage to the organism. Although the toxicity of the cholalate for red corpuscles, when free from serum, is at most only slightly diminished by conjugation, yet the blood serum possesses a greater inhibiting action for the resulting glycocholate than for the original cholalate. 4. As compared with its inhibition of sodium glycocholate, normal serum possesses relatively little inhibiting action against certain foreign hemolytic agents, such as tetanus toxin, sodium benzoate, phenol and ethyl alcohol. 5. Hemolytic experiments afford a fairly general method for studying, in vitro, certain syntheses occurring in the body. They avoid, largely, the complications, such as rapid chemical alteration, which might occur in animal experimentation. Contrary to the results obtained with bile salts, the conjugation of benzoic acid and of phenol results in an effective reduction of their hemolytic action independently of the presence or absence of serum.

Entities:  

Year:  1909        PMID: 19867284      PMCID: PMC2124749          DOI: 10.1084/jem.11.6.786

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  1 in total

1.  STUDIES ON THE TOTAL BILE : IV. THE ENTEROHEPATIC CIRCULATION OF BILE PIGMENT.

Authors:  G O Broun; P D McMaster; P Rous
Journal:  J Exp Med       Date:  1923-04-30       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.